You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

Certaines de ces informations ou toutes, dans certains cas, n’apparaissent qu’en Anglais. Vous pouvez demander la version française

Financement des régimes fondés sur les données probantes

Les monographies et fiches d’information sur les médicaments et les régimes à l’intention des patients offrent des renseignements sur la posologie et l’administration des traitements contre le cancer.

Elles ne sont fournies qu’à titre indicatif et ne visent pas à remplacer les renseignements posologiques ni les recommandations d’un médecin.

Si vous avez des questions à propos du financement des TS-PBQ, veuillez consulter la Foire aux questions (anglais) de notre site Web.

Découvrez les fiches d’information améliorées sur les régimes à l’intention des patients, élaborées en collaboration avec les conseillers des patients et des familles. Disponible en français.

Regimens

7 Items
Cancer Type: Hematologic, Multiple Myeloma     
Intent: Palliative
Funding:
New Drug Funding Program
    Bortezomib - Relapsed or Refractory Multiple Myeloma
New Drug Funding Program
    Daratumumab – In Combination with Bortezomib and Dexamethasone for Relapsed Multiple Myeloma
ODB - General Benefit
    dexamethasone
Sep 2019
Cancer Type: Hematologic, Multiple Myeloma     
Intent: Palliative
Funding:
New Drug Funding Program
    Daratumumab – In Combination with Bortezomib and Dexamethasone for Relapsed Multiple Myeloma
Dec 2019
Cancer Type: Hematologic, Multiple Myeloma     
Intent: Palliative
Funding:
New Drug Funding Program
    Daratumumab – In Combination with Lenalidomide and Dexamethasone for Relapsed Multiple Myeloma
ODB - General Benefit
    dexamethasone
Exceptional Access Program
    lenalidomide - For the treatment of patients with multiple myeloma with good performance status who have received at least one prior therapy.
Jul 2019
Cancer Type: Gastrointestinal, Colorectal, Small bowel and appendix     
Intent: Palliative
Funding:
New Drug Funding Program
    Irinotecan - First Line - Metastatic Colorectal Small Bowel or Appendiceal Cancer
New Drug Funding Program
    Panitumumab - In Combination with Chemotherapy for First Line Metastatic Colorectal Small Bowel or Appendiceal Cancer
Aug 2019
Cancer Type: Gastrointestinal, Colorectal, Small bowel and appendix     
Intent: Palliative
Funding:
New Drug Funding Program
    Oxaliplatin - First Line - Metastatic Colorectal Small Bowel or Appendiceal Cancer
New Drug Funding Program
    Panitumumab - In Combination with Chemotherapy for First Line Metastatic Colorectal Small Bowel or Appendiceal Cancer
Aug 2019
Cancer Type: Gastrointestinal, Colorectal, Small bowel and appendix     
Intent: Palliative
Funding:
New Drug Funding Program
    Panitumumab - Metastatic Colorectal Small Bowel or Appendiceal Cancer
Nov 2019
Cancer Type: Hematologic, Rare Diseases     
Intent: Palliative
Funding:
New Drug Funding Program
    Siltuximab - Multicentric Castleman’s Disease (MCD)
Nov 2017